Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.
We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.
We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.
Learn more about our Cardio Analysis Services
Experts in cardiac safety
Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.
Richmond promotes new Director of Communications and Participant Engagement
12
August 2024
Richmond Pharmacology is delighted to announce the promotion of Liz Romano to the new position of Director of Communications and Participant Engagement.
Richmond Chief Medical Director calls for a ‘toolbox’ of standards and guidelines for clinical trials
5
August 2024
The British Journal of Clinical Pharmacology has published an editorial by Richmond’s Dr Ulrike Lorch and Professor Charles Vincent of Oxford University calling for a ‘toolbox’ of practical standards and guidelines for early phase clinical trials.
Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease
27
June 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.